Pulmocide is a biopharmaceutical company with a mission to treat common acute and chronic respiratory tract infections associated with serious complications and devastating effects on patients’ quality of life.
Proteostasis Therapeutics
Proteostasis Therapeutics is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Proteostasis Therapeutics went public in 2016 (NASDAQ: PTI). The company merged with Yumanity Therapeutics in 2020 and is no longer traded with the ticker symbol PTI.
NovaMed Pharmaceuticals
NovaMed Pharmaceuticals is a revenue-generating specialty pharmaceutical company focused on the commercialization of branded innovative therapies for diseases with high unmet medical need in China, including oncology, urology, and cardiovascular. NovaMed was acquired by SciClone.
NextWave Pharmaceuticals
NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.
Mersana Therapeutics
Mersana Therapeutics (NASDAQ: MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
LigoCyte
LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.
Laurus Labs
Laurus Labs (NSE: LAURUSLABS) is a leading manufacturer of Active Pharmaceutical Ingredients (API) for anti-retroviral (HIV-AIDS), oncology, nutraceutical and several other products, with a customer base that spans top-tier generic pharmaceutical companies in India and abroad.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) developed linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation.
Ikano Therapeutics
Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.
Innovent Biologics
Innovent Biologics (1801.HK) has built a robust pipeline of innovative and commercially promising monoclonal antibodies and other biologics in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases.